[go: up one dir, main page]

ES2196547T3 - Tratamiento de infartos por inhibicion de nf-kappab. - Google Patents

Tratamiento de infartos por inhibicion de nf-kappab.

Info

Publication number
ES2196547T3
ES2196547T3 ES98906511T ES98906511T ES2196547T3 ES 2196547 T3 ES2196547 T3 ES 2196547T3 ES 98906511 T ES98906511 T ES 98906511T ES 98906511 T ES98906511 T ES 98906511T ES 2196547 T3 ES2196547 T3 ES 2196547T3
Authority
ES
Spain
Prior art keywords
kappab
infartos
inhibition
treatment
ubiquitin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98906511T
Other languages
English (en)
Inventor
Stephen Brand
Alfred L Goldberg
Louis Plamondon
Francois Soucy
Peter J Elliot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2196547T3 publication Critical patent/ES2196547T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Insulating Materials (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Artificial Filaments (AREA)
  • Transplanting Machines (AREA)
  • Investigation Of Foundation Soil And Reinforcement Of Foundation Soil By Compacting Or Drainage (AREA)

Abstract

La invención se refiere al tratamiento de la isquemia por medio de la administración de inhibidores de proteasoma, inhibidores de la ruta de ubiquitina, agentes que interfieren con la activación de NF-{ka}B por medio de la ruta de ubiquitina proteasoma, o mezclas de los mismos.
ES98906511T 1997-02-15 1998-02-17 Tratamiento de infartos por inhibicion de nf-kappab. Expired - Lifetime ES2196547T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80193697A 1997-02-15 1997-02-15
US98833997A 1997-12-03 1997-12-03

Publications (1)

Publication Number Publication Date
ES2196547T3 true ES2196547T3 (es) 2003-12-16

Family

ID=27122399

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98906511T Expired - Lifetime ES2196547T3 (es) 1997-02-15 1998-02-17 Tratamiento de infartos por inhibicion de nf-kappab.

Country Status (14)

Country Link
US (3) US6271199B2 (es)
EP (1) EP0979096B1 (es)
JP (1) JP2001511814A (es)
CN (1) CN1159061C (es)
AT (1) ATE240113T1 (es)
AU (1) AU741802B2 (es)
CA (1) CA2281224A1 (es)
DE (1) DE69814618T2 (es)
ES (1) ES2196547T3 (es)
IL (1) IL131410A0 (es)
NO (1) NO321203B1 (es)
NZ (1) NZ337364A (es)
PT (1) PT979096E (es)
WO (1) WO1998035691A1 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1008352A4 (en) * 1997-07-04 2005-03-16 Fujisawa Pharmaceutical Co Cerebrospinal PROTECTOR
US6133308A (en) 1997-08-15 2000-10-17 Millennium Pharmaceuticals, Inc. Synthesis of clasto-lactacystin beta-lactone and analogs thereof
US7175679B2 (en) 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
EP1138692A1 (en) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US6844315B2 (en) * 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US20030220258A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US8680059B2 (en) * 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US20090042807A1 (en) * 1998-05-20 2009-02-12 Nisar Ahmed Khan Oligopeptide treatment of ischemia reperfusion injury
AU763042B2 (en) * 1999-09-13 2003-07-10 Charlotte-Mecklenburg Hospital Authority Method of inhibiting NF-kappaB with heparin
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US7576174B2 (en) 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US6713459B1 (en) * 2000-04-28 2004-03-30 East Tennessee State University Methods for the prophylactic and therapeutic treatment of cardiac tissue damage
ES2402045T3 (es) * 2000-11-16 2013-04-26 The Regents Of The University Of California Taxón de actionomiceto marino para el descubrimiento de fármacos y de productos de fermentación
EP2251344B2 (en) 2001-01-25 2024-04-24 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Formulation of boronic acid compounds
ES2278049T3 (es) 2001-05-21 2007-08-01 Alcon, Inc. Uso de inhibidores de proteasoma para tratar trastornos de ojo seco.
US7112588B2 (en) 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
KR100824491B1 (ko) * 2001-10-05 2008-04-22 콤비네이토릭스, 인코포레이티드 면역염증 질환의 치료를 위한 조합
EP1461025B1 (en) * 2001-12-10 2011-07-27 Du, Yansheng, Dr. Treatment of parkinson's disease with cape
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US7786084B2 (en) * 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7501391B2 (en) 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
US7517529B2 (en) * 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
US20050004164A1 (en) * 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
EP2441767B1 (en) * 2003-06-20 2015-06-10 The Regents of The University of California Salinosporamides and methods for use thereof
NZ544588A (en) * 2003-06-20 2010-06-25 Nereus Pharmaceuticals Inc Use of salinosporamide A and analogs thereof for the treatment of cancer, inflammation and infectious diseases
US7348305B2 (en) * 2003-08-28 2008-03-25 Department Of Veterans Affairs, Rehabilitation Inhibitor of cardiac tachyarrhythmias
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
SE0400399D0 (sv) * 2004-02-20 2004-02-20 Index Pharmaceuticals Ab Methods and compositions for the treatment or prevention of secondary ischemic injury
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
EP2266988A1 (en) 2004-04-30 2010-12-29 Nereus Pharmaceuticals, Inc. [3.2.0] Heterocyclic compounds and methods of using the same
US7425580B2 (en) * 2004-05-19 2008-09-16 Wyeth (Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
US20060008454A1 (en) * 2004-07-07 2006-01-12 Dr. Helmut Brunar Use of a compound for enhancing the expression of membrane proteins on the cell surface
EP1771194A2 (en) * 2004-07-07 2007-04-11 Biodevelops Pharma Entwicklung GmbH Use of a deubiquitinating compound for enhancing the expression of membrane proteins on the cell surface
KR20070058463A (ko) * 2004-08-30 2007-06-08 도레이 가부시끼가이샤 분획 장치
US20060167106A1 (en) * 2004-11-19 2006-07-27 Mei Zhang Compounds acting at the centrosome
CN103230394B (zh) 2004-12-03 2016-04-20 达纳-法伯癌症研究公司 治疗肿瘤性疾病的化合物及其用途
SG163567A1 (en) * 2005-07-05 2010-08-30 Biotempt Bv Treatment of tumors
EP1912664A2 (en) * 2005-07-06 2008-04-23 Biodevelops Pharma Entwicklung GmbH Use of a compound for enhancing the expression of membrane proteins on the cell surface
CA2614959A1 (en) * 2005-07-14 2007-01-25 Myogen, Inc. Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart
US7691896B2 (en) * 2005-08-10 2010-04-06 President And Fellows Of Harvard College Analogs of salinosporamide A
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
ES2293834B1 (es) * 2006-07-20 2009-02-16 Consejo Superior Investig. Cientificas Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas.
WO2008095195A2 (en) * 2007-02-02 2008-08-07 Nereus Pharmaceuticals, Inc. Lyophilized formulations of salinosporamide a
WO2008100140A1 (en) * 2007-02-12 2008-08-21 Biotempt B.V. Treatment of trauma hemorrhage with short oligopeptides
US20080280968A1 (en) * 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
JP2011519975A (ja) 2008-05-12 2011-07-14 ネレアス ファーマシューティカルズ インコーポレイテッド プロテアソーム阻害剤としてのサリノスポラミド誘導体
BR122014008753A2 (pt) 2008-06-17 2015-12-29 Millennium Pharm Inc compostos de éster boronato e composições farmacêuticas dos mesmos
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EP2305285A1 (en) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Means and methods for treating ischemic conditions
JP5954728B2 (ja) 2010-01-22 2016-07-20 国立研究開発法人科学技術振興機構 蛋白質の分解活性を測定するためのプローブ試薬
CN106008570A (zh) 2010-03-31 2016-10-12 米伦纽姆医药公司 1-氨基-2-环丙基乙硼酸衍生物
LT2846809T (lt) 2012-05-09 2021-01-25 Cantex Pharmaceuticals, Inc. Mielosupresijos gydymas
EP2986619A1 (en) 2013-04-16 2016-02-24 Cipla Limited Process for the preparation of bortezomib mannitol ester
EP3102585B1 (en) 2014-02-03 2021-05-19 Ohio State Innovation Foundation Boronic acid esters and pharmaceutical formulations thereof
CN106659761A (zh) 2014-05-20 2017-05-10 千年药物公司 初级癌症疗法后使用的含硼蛋白酶体抑制剂
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
US20180243217A1 (en) 2015-03-17 2018-08-30 Leon-Nanodrugs Gmbh Nanoparticles comprising a stabilized boronic acid compound
EP3700567A4 (en) 2017-10-26 2021-09-29 The Regents of The University of California INHIBITION OF OXIDATION-SPECIFIC EPITOPIA TO TREAT REPERFUSION ISCHEMIC DAMAGE
AU2024240129A1 (en) 2023-03-17 2025-10-09 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2077665A1 (en) 1990-03-05 1991-09-06 Robert Siman Chymotrypsin-like proteases and their inhibitors
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
PT824918E (pt) * 1995-05-12 2007-06-22 Anges Mg Inc Tratamento e prevenção para doenças causadas pelo nf-kb
US5942494A (en) 1995-10-06 1999-08-24 The Trustees Of Columbia University In The City Of New York Stimulation of gene expression and synthesis of heat shock protein 72/73 (HSP 70)
JP2000510328A (ja) 1996-03-19 2000-08-15 プロスクリプト・インコーポレイテッド ＩкＢαを部位特異的にリン酸化し得るキナーゼ
US6133308A (en) 1997-08-15 2000-10-17 Millennium Pharmaceuticals, Inc. Synthesis of clasto-lactacystin beta-lactone and analogs thereof

Also Published As

Publication number Publication date
DE69814618T2 (de) 2004-03-25
AU741802B2 (en) 2001-12-13
CN1250376A (zh) 2000-04-12
US20010053760A1 (en) 2001-12-20
IL131410A0 (en) 2001-01-28
EP0979096A1 (en) 2000-02-16
US6271199B2 (en) 2001-08-07
JP2001511814A (ja) 2001-08-14
ATE240113T1 (de) 2003-05-15
PT979096E (pt) 2003-09-30
CA2281224A1 (en) 1998-08-20
NO321203B1 (no) 2006-04-03
WO1998035691A1 (en) 1998-08-20
CN1159061C (zh) 2004-07-28
EP0979096B1 (en) 2003-05-14
US20010002391A1 (en) 2001-05-31
HK1025266A1 (en) 2000-11-10
US20030069189A1 (en) 2003-04-10
NZ337364A (en) 2001-06-29
NO993935L (no) 1999-10-04
AU6171998A (en) 1998-09-08
NO993935D0 (no) 1999-08-16
DE69814618D1 (de) 2003-06-18

Similar Documents

Publication Publication Date Title
ES2196547T3 (es) Tratamiento de infartos por inhibicion de nf-kappab.
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
DK0840732T3 (da) Substituerede benzolactamforbindelser som substans P-antagonister
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
BG104247A (en) Resorcinol derivatives
BRPI0410888A (pt) uso de derivados de difenilmetano como inibidores de tirosinase
DE69825048D1 (de) Analoga von duocarmycin and cc-1065
TR199701074T1 (xx) Sinerjistik bile�imler.
AP9200410A0 (en) Retroviral protease inhibitors.
TR199902751T2 (xx) Proteaz inhibit�rleri.
BR9812357A (pt) Tratamento de distúbio oposicional desafiador
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
ES2167678T3 (es) Tratamiento y profilaxis de la pancreatitis.
DE69912743D1 (de) Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)-aktivierungsweges
BR9808299A (pt) O uso de levobupivacaìna ou ropivacaìna para o tratamento da enxaqueca
DE60029463D1 (de) Behandlung von dyskinesie
ATE322898T1 (de) Inhibitoren von mycobakterien
PT1042288E (pt) Inibidores de tripeptidil peptidase
ID27052A (id) Pengobatan arthritis dan keadaan-keadaan lain yang sekupa
SE9800139D0 (sv) New use
BR0210678A (pt) Carbamatos de 2-heterocìclicos-1,2-etanodióis
ES2173634T3 (es) Compuestos heterociclicos que presentan actividad inhibidora de mmp y tnf.
YU51802A (sh) Nova terapeutska primena enoksaparina